Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience
This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D...
Gespeichert in:
Veröffentlicht in: | Molecular and clinical oncology 2013-03, Vol.1 (2), p.337-342 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 342 |
---|---|
container_issue | 2 |
container_start_page | 337 |
container_title | Molecular and clinical oncology |
container_volume | 1 |
creator | FURUBAYASHI, NOBUKI NAKAMURA, MOTONOBU HISHIKAWA, KEN FUKUDA, ATSUSHI MATSUMOTO, TAKASHI NISHIYAMA, KENICHI YAMANAKA, TAKEHARU HASEGAWA, YOSHIHIRO |
description | This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients. |
doi_str_mv | 10.3892/mco.2012.39 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3956272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826593599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</originalsourceid><addsrcrecordid>eNpdkc1rFTEUxYMottSu3EvAhYWS13zNZOJCKMWqUBCKrkOaufNe6kwyJhlp_3tT3nNQs7nh3t89nOQg9JrRjeg0v5hc3HDK-EboZ-iYU6mJlq1-vt4beoROc76n9WhFeaNfoiMuW6mZ4sco3NreOzviOcVcbAFX4vSIbcbpMHBLAhyHFcDOBgcJ-4At3vntjiSff-Btisv8Hl_i7MN2BOJDLr4sxceA4WGG5KGuvUIvBjtmOD3UE_T9-uO3q8_k5uunL1eXN8QJxQpRQmoqBsmkslw55rpuuGu07VkvtXPQOFo7rG8piKEivegGYLq1Sko5gBMn6MNed17uJugdhJLsaObkJ5seTbTe_DsJfme28ZcRumm54lXg7CCQ4s8FcjGTzw7G0QaISzas422jRaN1Rd_-h97HJYX6PMO04LIRvFWVOt9Trv5jTjCsZhg1T1GaGqV5irJ6qPSbv_2v7J_gKvBuD-TZht73Ma9M1SGUEcoJFUKJ34KIqJQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932453267</pqid></control><display><type>article</type><title>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>FURUBAYASHI, NOBUKI ; NAKAMURA, MOTONOBU ; HISHIKAWA, KEN ; FUKUDA, ATSUSHI ; MATSUMOTO, TAKASHI ; NISHIYAMA, KENICHI ; YAMANAKA, TAKEHARU ; HASEGAWA, YOSHIHIRO</creator><creatorcontrib>FURUBAYASHI, NOBUKI ; NAKAMURA, MOTONOBU ; HISHIKAWA, KEN ; FUKUDA, ATSUSHI ; MATSUMOTO, TAKASHI ; NISHIYAMA, KENICHI ; YAMANAKA, TAKEHARU ; HASEGAWA, YOSHIHIRO</creatorcontrib><description>This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.</description><identifier>ISSN: 2049-9450</identifier><identifier>EISSN: 2049-9469</identifier><identifier>DOI: 10.3892/mco.2012.39</identifier><identifier>PMID: 24649172</identifier><language>eng</language><publisher>England: D.A. Spandidos</publisher><subject>Biopsy ; Cancer surgery ; Cancer therapies ; Classification ; D'Amico classification ; Health risk assessment ; high-risk group ; Lymphatic system ; Medical prognosis ; Metastasis ; Oncology ; Patients ; Prostate cancer ; prostate-specific antigen failure ; radical prostatectomy ; Surgery ; Urological surgery</subject><ispartof>Molecular and clinical oncology, 2013-03, Vol.1 (2), p.337-342</ispartof><rights>Copyright © 2013, Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2013</rights><rights>Copyright © 2013, Spandidos Publications 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</citedby><cites>FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956272/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956272/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,5556,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24649172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FURUBAYASHI, NOBUKI</creatorcontrib><creatorcontrib>NAKAMURA, MOTONOBU</creatorcontrib><creatorcontrib>HISHIKAWA, KEN</creatorcontrib><creatorcontrib>FUKUDA, ATSUSHI</creatorcontrib><creatorcontrib>MATSUMOTO, TAKASHI</creatorcontrib><creatorcontrib>NISHIYAMA, KENICHI</creatorcontrib><creatorcontrib>YAMANAKA, TAKEHARU</creatorcontrib><creatorcontrib>HASEGAWA, YOSHIHIRO</creatorcontrib><title>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</title><title>Molecular and clinical oncology</title><addtitle>Mol Clin Oncol</addtitle><description>This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.</description><subject>Biopsy</subject><subject>Cancer surgery</subject><subject>Cancer therapies</subject><subject>Classification</subject><subject>D'Amico classification</subject><subject>Health risk assessment</subject><subject>high-risk group</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>prostate-specific antigen failure</subject><subject>radical prostatectomy</subject><subject>Surgery</subject><subject>Urological surgery</subject><issn>2049-9450</issn><issn>2049-9469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkc1rFTEUxYMottSu3EvAhYWS13zNZOJCKMWqUBCKrkOaufNe6kwyJhlp_3tT3nNQs7nh3t89nOQg9JrRjeg0v5hc3HDK-EboZ-iYU6mJlq1-vt4beoROc76n9WhFeaNfoiMuW6mZ4sco3NreOzviOcVcbAFX4vSIbcbpMHBLAhyHFcDOBgcJ-4At3vntjiSff-Btisv8Hl_i7MN2BOJDLr4sxceA4WGG5KGuvUIvBjtmOD3UE_T9-uO3q8_k5uunL1eXN8QJxQpRQmoqBsmkslw55rpuuGu07VkvtXPQOFo7rG8piKEivegGYLq1Sko5gBMn6MNed17uJugdhJLsaObkJ5seTbTe_DsJfme28ZcRumm54lXg7CCQ4s8FcjGTzw7G0QaISzas422jRaN1Rd_-h97HJYX6PMO04LIRvFWVOt9Trv5jTjCsZhg1T1GaGqV5irJ6qPSbv_2v7J_gKvBuD-TZht73Ma9M1SGUEcoJFUKJ34KIqJQ</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>FURUBAYASHI, NOBUKI</creator><creator>NAKAMURA, MOTONOBU</creator><creator>HISHIKAWA, KEN</creator><creator>FUKUDA, ATSUSHI</creator><creator>MATSUMOTO, TAKASHI</creator><creator>NISHIYAMA, KENICHI</creator><creator>YAMANAKA, TAKEHARU</creator><creator>HASEGAWA, YOSHIHIRO</creator><general>D.A. Spandidos</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130301</creationdate><title>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</title><author>FURUBAYASHI, NOBUKI ; NAKAMURA, MOTONOBU ; HISHIKAWA, KEN ; FUKUDA, ATSUSHI ; MATSUMOTO, TAKASHI ; NISHIYAMA, KENICHI ; YAMANAKA, TAKEHARU ; HASEGAWA, YOSHIHIRO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-734903f4147a27c1c88fb59ad1d49cce5c088f1d60e3f7a2d38fe196a7444fec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biopsy</topic><topic>Cancer surgery</topic><topic>Cancer therapies</topic><topic>Classification</topic><topic>D'Amico classification</topic><topic>Health risk assessment</topic><topic>high-risk group</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>prostate-specific antigen failure</topic><topic>radical prostatectomy</topic><topic>Surgery</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FURUBAYASHI, NOBUKI</creatorcontrib><creatorcontrib>NAKAMURA, MOTONOBU</creatorcontrib><creatorcontrib>HISHIKAWA, KEN</creatorcontrib><creatorcontrib>FUKUDA, ATSUSHI</creatorcontrib><creatorcontrib>MATSUMOTO, TAKASHI</creatorcontrib><creatorcontrib>NISHIYAMA, KENICHI</creatorcontrib><creatorcontrib>YAMANAKA, TAKEHARU</creatorcontrib><creatorcontrib>HASEGAWA, YOSHIHIRO</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FURUBAYASHI, NOBUKI</au><au>NAKAMURA, MOTONOBU</au><au>HISHIKAWA, KEN</au><au>FUKUDA, ATSUSHI</au><au>MATSUMOTO, TAKASHI</au><au>NISHIYAMA, KENICHI</au><au>YAMANAKA, TAKEHARU</au><au>HASEGAWA, YOSHIHIRO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience</atitle><jtitle>Molecular and clinical oncology</jtitle><addtitle>Mol Clin Oncol</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>1</volume><issue>2</issue><spage>337</spage><epage>342</epage><pages>337-342</pages><issn>2049-9450</issn><eissn>2049-9469</eissn><abstract>This study aimed to evaluate the possibility of performing radical prostatectomy (RP) alone to achieve radical cure of prostate cancer in a high-risk group. Between August 1998 and December 2008, 436 Japanese patients underwent antegrade RP following the exclusion of 139 patients. According to the D'Amico criteria, the low-, intermediate- and high-risk groups comprised 63, 122 and 112 patients, respectively. Twenty-five patients who were classified into the high-risk group based only on T2c stage, were evaluated as a separate intermediate/high-risk group. Results of the multivariate analysis revealed that of the preoperative characteristics only a biopsy Gleason score was a significant predictor in patients with and without PSA failure (P=0.017). After a median follow-up period of 60 months, the PSA failure-free rates in the low-, intermediate-, high- and intermediate/high-risk groups were 96.5, 92.2, 76.8 and 95.0%, respectively. No statistically significant difference was detected in the high- and intermediate/high-risk groups (P=0.064). Thus, patients classified into the high-risk group based on cT2 stage only, are considered to be potentially eligible for radical treatment by surgery alone, and should not be evaluated as high-risk patients.</abstract><cop>England</cop><pub>D.A. Spandidos</pub><pmid>24649172</pmid><doi>10.3892/mco.2012.39</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2049-9450 |
ispartof | Molecular and clinical oncology, 2013-03, Vol.1 (2), p.337-342 |
issn | 2049-9450 2049-9469 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3956272 |
source | Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Biopsy Cancer surgery Cancer therapies Classification D'Amico classification Health risk assessment high-risk group Lymphatic system Medical prognosis Metastasis Oncology Patients Prostate cancer prostate-specific antigen failure radical prostatectomy Surgery Urological surgery |
title | Radical prostatectomy as radical cure of prostate cancer in a high-risk group: A single-institution experience |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A37%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radical%20prostatectomy%20as%20radical%20cure%20of%20prostate%20cancer%20in%20a%20high-risk%20group:%20A%20single-institution%20experience&rft.jtitle=Molecular%20and%20clinical%20oncology&rft.au=FURUBAYASHI,%20NOBUKI&rft.date=2013-03-01&rft.volume=1&rft.issue=2&rft.spage=337&rft.epage=342&rft.pages=337-342&rft.issn=2049-9450&rft.eissn=2049-9469&rft_id=info:doi/10.3892/mco.2012.39&rft_dat=%3Cproquest_pubme%3E1826593599%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932453267&rft_id=info:pmid/24649172&rfr_iscdi=true |